References
- Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2013. Available from: www.cibmtr.org
- Martin N, Borchiellini D, Coso D, et al. High-dose chemotherapy with full carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma 2015;56:2379–2387.
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
- Artz A. Older patients/older donors: choosing wisely. Hematology Am Soc Hematol Educ Program 2013:70–75.
- Bhatt VR, Vose JM. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. Hematol Oncol Clin North Am 2014;28: 1073–1095.
- Waterstrat A, Van Zant G. Effects of ageing on hematopoietic stem cell and progenitor cells. Curr Opin Immunol 2009;21:408–413.
- Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008;93:1837–1842.
- Dahi PB, Tamari R, Devlin SM, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20:2004–2009.
- Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005;46:1575–1579.
- Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:840–846.
- Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:1031–1035.
- Hosing C, Saliba RM, Okoroji GJ, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients > 65 years of age. Ann Oncol 2008;19:1166–1171.
- Elstrom RL, Martin P, Hurtado Rua S, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol 2012;87:433–435.
- Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588–595.
- Plattel WJ, Kluin-Nelemans HC, de Bock GH, et al. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2011;46:827–834.
- Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large B cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547–4553.
- Sarkozy C, Camus V, Tilly H, et al. Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. Leuk Lymphoma 2015;56:1959–1968.